6505--Rituximab and Biosimilars
ID: 36E79725R0021Type: Presolicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/f54810a5b77f424297b8eb9d6097413f/view
Timeline
    Description

    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) designated as 36E79725R0021 for the procurement of Rituximab and its biosimilars, aimed at ensuring a reliable supply for various federal entities, including the Department of Defense and the Bureau of Prisons. The contract will span one year with four additional one-year options, emphasizing the necessity of maintaining an uninterrupted supply chain for these critical medications. Offerors must provide the exact product names along with unique National Drug Codes (NDC), with estimated annual requirements of 17,858 vials of Rituximab 10mg/ml and 25,111 vials of the 50mg/ml variant. The solicitation is expected to be published around February 17, 2025, with a closing date around March 4, 2025; interested parties should direct inquiries to Deb Fassl at Deborah.Fassl@va.gov.

    Point(s) of Contact
    Deb FasslContract Specialist
    (708) 786-5894
    Deborah.Fassl@va.gov
    Files
    Title
    Posted
    36E79725R0021_1.docx
    The Department of Veterans Affairs (VA) is preparing to release a Request for Proposal (RFP) designated as 36E79725R0021 for the procurement of Rituximab and its biosimilars. This RFP aims to secure a reliable supply of these medications for various federal entities, including the Department of Defense and the Bureau of Prisons. The contract, which will span one year with four additional one-year options, emphasizes the importance of maintaining an uninterrupted supply chain. The solicitation is scheduled to be published around February 17, 2025, with a closing date around March 4, 2025. Offerors must provide the exact product names along with unique National Drug Codes (NDC). The estimated requirements include 17,858 vials of Rituximab 10mg/ml and 25,111 vials of the 50mg/ml variant annually. Notably, any proposed biosimilars must be FDA-approved and comply with regulatory standards laid out under 42 U.S.C. § 262. The RFP documentation and further amendments will be electronically available through the SAM website, with no paper copies distributed. The point of contact for this RFP is Deb Fassl, reachable via email for inquiries.
    Lifecycle
    Title
    Type
    6505--Rituximab and Biosimilars
    Currently viewing
    Presolicitation
    Similar Opportunities
    6505--Bevacizumab Injection
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to procure Bevacizumab Injections through a Request for Proposal (RFP) designated as 36E79725R0019. This procurement aims to secure an uninterrupted supply of Bevacizumab, a critical pharmaceutical product used in the treatment of various medical conditions, for the VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The contract will span one year with four additional one-year option periods, and the estimated annual requirements include various package sizes of Bevacizumab, with a total estimated usage of over 100,000 vials. Interested offerors must submit their proposals by March 4, 2025, at 2:30 PM Central Time, and can direct inquiries to Contract Specialist Matthew Poulin at Matthew.Poulin@va.gov or by phone at 708-786-5186.
    6505--Mycophenolate Mofetil RFP
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) numbered 36E79725R0010 for the procurement of Mycophenolate Mofetil tablets and capsules, intended for use by the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The procurement aims to secure a reliable source of supply for these essential medications, with a contract term of one year and the option to extend for four additional years, emphasizing the importance of uninterrupted access to critical pharmaceuticals for veterans and associated federal programs. Interested offerors must comply with specific packaging requirements, including child-resistant closures for smaller bottles, and are encouraged to check the designated URL for updates, with the solicitation expected to be issued around February 14, 2025, and offers accepted until February 28, 2025. For inquiries, potential bidders can contact Amber Zavala at amber.zavala@va.gov or by phone at (708) 786-5245.
    6505--Fluticasone Propionate 50 MCG/Spray Soln, Nasal, 16GM
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Fluticasone Propionate 50 MCG/Spray solution, nasal, 16GM, intended for use by various federal agencies including the Department of Defense, Bureau of Prisons, and Indian Health Service. The objective of this procurement is to secure a reliable and uninterrupted supply of this medication for a contract period of one year, with the possibility of four additional one-year extensions. This medication is crucial for treating nasal conditions, and the estimated annual requirement is approximately 5,784,828 bottles. The solicitation will be available electronically on or around February 11, 2025, with a closing date set for February 25, 2025. Interested vendors should direct inquiries to Michael Olszewski at michael.olszewski@va.gov or call 708-786-4966.
    6505--Phenytoin SA Capsules (VA-25-00022318)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to issue a Request for Proposal (RFP) for the procurement of Phenytoin Sodium Extended 100MG Sustained Action Capsules, designated as solicitation number 36E79725R0016. This unrestricted contract aims to ensure a reliable supply of these essential medications for the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS), with one contract awarded for an initial period of one year and the option for four additional one-year periods. The estimated annual requirement is approximately 16,653 units, highlighting the critical need for uninterrupted supply to support service members and associated organizations. Interested offerors should submit their proposals by March 7, 2025, following the electronic issuance of the RFP on or about February 21, 2025, and may direct inquiries to Contract Specialist Youlanda Duggar at youlanda.duggar@va.gov.
    6505--Baclofen Tablets (VA-25-00026620)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the supply of Baclofen Tablets under the solicitation titled "6505--Baclofen Tablets (VA-25-00026620)." The primary objective of this procurement is to establish a reliable source for various strengths of Baclofen tablets, ensuring consistent availability and quality at pre-negotiated prices, while complying with the Drug Supply Chain Security Act and Good Manufacturing Practices. This contract is crucial for maintaining the pharmaceutical needs of VA facilities, addressing issues such as compliance, backorders, and recalls. Interested offerors must submit their proposals by February 5, 2025, at 2:30 PM CST, and can direct inquiries to Contracting Officer Adrienne A Albachiara at Adrienne.Albachiara@va.gov.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Rizatriptan Benzoate
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.
    6515--Pharmacy Management System ScriptPro Brand name or Equal
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for the procurement of a ScriptPro Pharmacy Management System or an equivalent solution, as outlined in the combined synopsis/solicitation RFQ 36C26225Q0148. This procurement aims to enhance pharmacy management capabilities across various Veterans Integrated Service Network (VISN) 22 medical facilities and clinics, ensuring high-quality healthcare service delivery through reliable technological advancements. Interested vendors are encouraged to participate, particularly small businesses, including those owned by veterans and women, with bids due by February 4, 2025, at 7:00 AM PST. For inquiries, potential bidders should contact Contracting Officer Anthony Dela Cruz at anthony.delacruz@va.gov or by phone at 562-766-2284.
    6505--Domestic Pharmaceuticals/Med/Surge
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is conducting a Sources Sought notice to identify qualified domestic pharmaceutical manufacturers capable of supplying a range of medications for the Consolidated Mail Outpatient Pharmacy (CMOP). The procurement aims to ensure a reliable supply of domestically manufactured pharmaceuticals, including glucose test strips, hypertension treatments, and various other essential medications. This initiative is crucial for maintaining the health and well-being of veterans, as it supports ongoing healthcare needs. Interested manufacturers must submit their capability statements by February 5, 2025, to Josie Linaweaver at josie.linaweaver@va.gov, and are reminded to register in the System for Award Management (SAM) prior to contract award.
    6505--Tamsulosin Capsules
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the procurement of Tamsulosin Hydrochloride capsules as part of its Pharmaceutical Prime Vendor (PPV) Programs. Offerors are required to submit pricing for a base year and four option years, ensuring compliance with FDA standards and providing a unique 11-digit National Drug Code (NDC) for each product. This procurement is vital for maintaining a consistent supply of necessary pharmaceuticals to federal healthcare facilities, adhering to regulatory standards while ensuring availability and pricing stability. Interested parties must submit their offers by February 24, 2025, at 2:30 PM CST, and can contact Contract Specialist Andrew J. Cazares at Andrew.Cazares@va.gov for further information.